Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (61-70 of 616) with videos related to

Pageof 62
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 28, 2020
DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, et al.
The Journal of Infectious Diseases|September 13, 2023
Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan AfricaJustine Umutesi, Ming-Lung Yu, Olufunmilayo Lesi, et al.
Medicine|November 29, 2016
Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case reportChung-Feng Huang, Tyng-Yuan Jang, Po-Liang Lu, et al.
Clinical and Molecular Hepatology|July 1, 2024
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication"Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Clinical and Molecular Hepatology|March 4, 2025
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stageTeng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, et al.
Hepatology (Baltimore, Md.)|August 30, 2008
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposureMing-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, et al.
Journal of Hepatology|November 18, 2008
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivityChing-I Huang, Chia-Yen Dai, Jee-Fu Huang, et al.
The Kaohsiung Journal of Medical Sciences|October 22, 2020
Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC studyMing-Lung Yu, Wei-Lun Tsai, Chi-Jen Chu, et al.
Travel Medicine and Infectious Disease|July 3, 2020
Familial clusters of the 2019 novel coronavirus diseases in TaiwanChia-Yen Dai, Ming-Lung Yu, Yuh-Jyh Jong, et al.
The Kaohsiung Journal of Medical Sciences|December 10, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease After Hepatitis C Virus CureChung-Feng Huang, Jee-Fu Huang, Ming-Lung Yu, et al.
Pageof 62

Showing results (61-70 of 616) with videos related to

Sort By:
Pageof 62
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 28, 2020
DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, et al.
The Journal of Infectious Diseases|September 13, 2023
Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan AfricaJustine Umutesi, Ming-Lung Yu, Olufunmilayo Lesi, et al.
Medicine|November 29, 2016
Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case reportChung-Feng Huang, Tyng-Yuan Jang, Po-Liang Lu, et al.
Clinical and Molecular Hepatology|July 1, 2024
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication"Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Clinical and Molecular Hepatology|March 4, 2025
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stageTeng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, et al.
Hepatology (Baltimore, Md.)|August 30, 2008
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposureMing-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, et al.
Journal of Hepatology|November 18, 2008
What can be revealed by extending the sensitivity of HBsAg detection to below the present limit? Beyond the applause for higher sensitivityChing-I Huang, Chia-Yen Dai, Jee-Fu Huang, et al.
The Kaohsiung Journal of Medical Sciences|October 22, 2020
Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC studyMing-Lung Yu, Wei-Lun Tsai, Chi-Jen Chu, et al.
Travel Medicine and Infectious Disease|July 3, 2020
Familial clusters of the 2019 novel coronavirus diseases in TaiwanChia-Yen Dai, Ming-Lung Yu, Yuh-Jyh Jong, et al.
The Kaohsiung Journal of Medical Sciences|December 10, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease After Hepatitis C Virus CureChung-Feng Huang, Jee-Fu Huang, Ming-Lung Yu, et al.
Pageof 62